HUM Humana Inc

$259.06

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending
Expected on
Report Time: Unknown Release Time
The Whisper Number
Consensus Estimate:
Revenue Estimate:

Latest Earnings Insight

As Humana approaches its earnings announcement on November 5, all eyes are on its strategic focus on expanding Medicare Advantage offerings, a move that has been pivotal in driving growth in recent quarters. With a market cap of nearly $35 billion, Humana is a significant player in the healthcare sector, and its performance is closely watched. Analysts have set an EPS estimate of $2.93, while the whisper number suggests a slightly more optimistic $3.19, reflecting market anticipation of stronger-than-expected results. Revenue is projected at $32 billion, underscoring the company's robust position in the industry. Investors will be keen to see if Humana can exceed these expectations, particularly given the competitive landscape and the company's ongoing efforts to enhance its service offerings and customer base.

Updated On 1/6/2026

About Humana Inc

Humana Inc. is a for-profit American health insurance company based in Louisville, Kentucky.

Website: https://www.humana.com

Sector
FINANCE
Industry
HOSPITAL & MEDICAL SERVICE PLANS
Exchange
NYSE
Country
USA
Currency
USD
Fiscal Year End
December
CIK
49071
Address
500 W MAIN ST, LOUISVILLE, KY, US
Valuation
Market Cap
$31.92B
P/E Ratio
26.53
PEG Ratio
0.80
Price to Book
1.95
Performance
EPS
$9.97
Dividend Yield
1.34%
Profit Margin
1.02%
ROE
7.41%
Technicals
50D MA
$265.84
200D MA
$296.90
52W High
$402.60
52W Low
$211.87
Fundamentals
Shares Outstanding
121M
Target Price
$307.01
Beta
0.63

HUM EPS Estimates vs Actual

Estimated
Actual

HUM News & Sentiment

Dec 31, 2025 • MarketBeat NEUTRAL
Humana Inc. $HUM Shares Purchased by VIRGINIA RETIREMENT SYSTEMS ET Al
VIRGINIA RETIREMENT SYSTEMS ET Al significantly increased its stake in Humana Inc. (NYSE:HUM) by 63.8% in the third quarter, now owning 188,664 shares valued at approximately $49.1 million. Humana exceeded Q3 earnings estimates with $3.24 EPS and reported $32.65 billion in revenue, an 11.1% year-over-year increase. Despite analyst consensus being a "Hold" rating with an average target price of $294.32, the company declared a quarterly dividend of $0.885 per share.
Dec 30, 2025 • Austin American-Statesman BEARISH
Oracle facing possible class action over data breaches impacting millions
Oracle, the Austin-based tech giant, is facing a potential class-action lawsuit following multiple data breaches this year that impacted millions of people. A federal judge in Austin is considering consolidating over 30 related cases into one. These lawsuits stem from at least two data breaches of Oracle's E-Business Suite by the cybercriminal group Cl0p, which harvested sensitive personal information and is now attempting to extort payments from affected companies.
Dec 30, 2025 • The Globe and Mail NEUTRAL
Why Humana Deserves Patience Now: Too Early to Buy, Too Risky to Sell
Humana Inc. has faced investor scrutiny due to rising medical costs and Medicare Advantage uncertainties but has shown relative resilience compared to its peers. While near-term buying isn't compelling due to valuation and ongoing pressures, its long-term investment case is supported by its strong market position and demographic tailwinds. Current investors are advised patience, and new investors to monitor cost trends and reimbursement clarity.
Dec 30, 2025 • Finviz NEUTRAL
Why Humana Deserves Patience Now: Too Early to Buy, Too Risky to Sell
Humana Inc. (HUM) has faced investor scrutiny due to rising medical costs and regulatory uncertainties, yet its stock has shown relative resilience compared to peers. While the company is not an immediate "buy" given its valuation and near-term pressures, its long-term prospects in Medicare Advantage, coupled with an aging U.S. population, suggest that abandoning the stock outright would be premature. Investors currently holding HUM should exercise patience as margin initiatives and normalized utilization trends could lead to a gradual recovery.
Dec 30, 2025 • Benzinga SOMEWHAT-BULLISH
Looking Into Centene Corp's Recent Short Interest
Centene Corp's (NYSE: CNC) short interest has decreased by 6.98% since its last report, with 12.59 million shares currently sold short, representing 2.93% of available shares. It would take traders an average of 1.97 days to cover their short positions. Compared to its peers, Centene Corp has less short interest, indicating a potentially more bullish sentiment from investors.
Dec 30, 2025 • Yahoo Finance NEUTRAL
Why Humana Deserves Patience Now: Too Early to Buy, Too Risky to Sell
Humana Inc. has navigated increasing medical costs and regulatory uncertainties, causing its stock to fluctuate. While immediate buying opportunities are limited due to valuation and ongoing pressures, the company's strong position in the Medicare Advantage market and long-term tailwinds suggest patience for current investors is warranted. New investors are advised to monitor trends before committing.
Sentiment Snapshot

Average Sentiment Score:

0.089
50 articles with scored sentiment

Overall Sentiment:

Neutral

HUM Reported Earnings

Jul 30, 2025
Jun 30, 2025 (Post market)
0.4 Surprise
  • Reported EPS: $6.27
  • Estimate: $5.87
  • Whisper:
  • Surprise %: 6.8%
Apr 30, 2025
Mar 31, 2025 (Pre market)
1.51 Surprise
  • Reported EPS: $11.58
  • Estimate: $10.07
  • Whisper:
  • Surprise %: 15.0%
Feb 11, 2025
Dec 31, 2024 (Pre market)
-0.04 Surprise
  • Reported EPS: $-2.16
  • Estimate: $-2.12
  • Whisper:
  • Surprise %: -1.9%
Oct 30, 2024
Sep 30, 2024 (Pre market)
0.77 Surprise
  • Reported EPS: $4.16
  • Estimate: $3.39
  • Whisper:
  • Surprise %: 22.7%
Jul 31, 2024
Jun 30, 2024 (Pre market)
1.1 Surprise
  • Reported EPS: $6.96
  • Estimate: $5.86
  • Whisper:
  • Surprise %: 18.8%
Apr 24, 2024
Mar 31, 2024 (Pre market)
1.23 Surprise
  • Reported EPS: $7.23
  • Estimate: $6.00
  • Whisper:
  • Surprise %: 20.5%
Jan 25, 2024
Dec 31, 2023 (Pre market)
-1.03 Surprise
  • Reported EPS: $-0.11
  • Estimate: $0.92
  • Whisper:
  • Surprise %: -112.0%
Nov 01, 2023
Sep 30, 2023 (Pre market)
0.61 Surprise
  • Reported EPS: $7.78
  • Estimate: $7.17
  • Whisper:
  • Surprise %: 8.5%
Aug 02, 2023
Jun 30, 2023 (Pre market)
0.11 Surprise
  • Reported EPS: $8.94
  • Estimate: $8.83
  • Whisper:
  • Surprise %: 1.2%

Financials